Pertuzumab biosimilar - EirGenix
Alternative Names: EG-1206A; PerjetaLatest Information Update: 06 Oct 2026
At a glance
- Originator EirGenix
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 06 Oct 2026 EirGenix plans to file MAA and BLA with EMA and US FDA, respectively (EirGenix pipeline, October 2026)
- 12 Nov 2025 Pertuzumab biosimilar is still in phase I trials for Breast cancer in Germany
- 12 Nov 2025 Sandoz in-licenses pertuzumab biosimilar from EirGenix, worldwide, excluding Taiwan, China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines and Japan